HSBC initiated coverage of Repligen (RGEN) with a Buy rating and $150 price target While biotech funding and the regulatory environment are headwinds for the company, its volume leverage in a recovery is underappreciated, the analyst tells investors in a research note. The firm believes Repligen’s portfolio in bioprocessing can drive double-digit revenue growth.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN: